Author Archives: Ines Martins, PhD

HCDR1 Therapy Has Positive Impact on Sjogren Syndrome as Well as Lupus, Its Maker XTL Reports

A therapy that XTL Biopharmaceuticals is developing for autoimmune diseases significantly reduced the expression of several cell signaling molecules called cytokines that play a role in the development of Sjögren’s syndrome (SS) associated with lupus, the company reported. The news came in a press release updating XTL’s efforts to develop hCDR1 for systemic…

Aurinia to Present Good News on LN Voclosporin Trial at Upcoming Lupus Meet in Australia

Canada’s Aurinia Pharmaceuticals will report positive results from its 48-week AURION clinical trial evaluating voclosporin for lupus nephritis (LN) treatment. The presentation will take place at the 12th International Congress on Systemic Lupus Erythematosus (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017), to be held March 26-29 in Melbourne,…

My Favorite Four Super Foods For Lupus

Two years ago the Paleo Diet was the diet everyone was talking about. I remember going to a New Years Eve party and they served paleo chili with cauliflower. It may sound very Californian, but it was honestly the best chili I ever had. I remember…

Neovacs to Give Update on Potential Lupus Vaccine, Now in Phase 2 Trial, at Conference

Neovacs will present an update on the company’s interferon alpha (IFNα) Kinoid vaccine program for lupus, dermatomyositis and type 1 diabetes at the upcoming 2017 Keystone Symposia Conference taking place in Banff, Alberta, Canada. Géraldine Grouard-Vogel, PhD, the company’s chief scientific officer, is set to give the  presentation — “Overexpression of IFNalpha…

CDC: Arthritis Disables One in Four American Adults

About 54 million Americans have been diagnosed with arthritis — a debilitating joint disease that takes many forms including lupus and rheumatoid arthritis — and 24 million are disabled by some sort of the disease. That means one in four Americans is living with the disease today, up 20 percent since 2002,…

Voclosporin Meets 48-Week Remission Endpoints in Phase 2b Trial for Lupus Nephritis

Voclosporin has met complete and partial remission endpoints in a clinical trial in patients with lupus nephritis (LN), said Canada’s Aurinia Pharmaceuticals. AURA-LV was a randomized, controlled double-blind Phase 2b clinical trial (NCT02141672) that compared the efficacy and safety of voclosporin with placebo in achieving remission in patients with LN, one of…